Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

216 Applying Pharmacogenomics in Therapeutics
2. Which of the following genes has been extensively studied in the treatment
response to depression?
a. SLC6A4
b. MAO
c. Stress hormone system
d. Nitric oxide
3. Possession of which of the following genotypes, according to current literature,
appears to be protective against the development of tardive dyskinesia?
a. DRD3 rx6280
b. T allele of rs1800497
c. HLA-DQB1 6672 G>C
d. C allele of rx381929
4. Which of the following genes should be genotyped prior to the initiation of
carbamazepine in the population of Asian ancestry?
a. SLC6A4
b. DRD3
c. HLA-B*1502
d. CYP3A4
5. Which of the following drugs would show an increase in blood levels if
smoking was restricted in a person who smokes?
a. Olanzapine
b. Quetiapine
c. Lurasidone
d. Aripiprazole
Answer Key
1. c
2. a
3. b
4. c
5. a
REFERENCES
1. FDA. Table of pharmacogenomic biomarkers in drug labels. Available from: http://
www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm
(accessed February 24, 2015).
2. Malhota AK, Zhang JP, Lencz T. Pharmacogenetics in psychiatry: Translating research
into clinical practice. Mol Psychiatry 2012;8:760–769.
3. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: Are we ready for widespread
clinical use? Schizophr Bull 2008;6:1130–1144.
4. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response
to antipsychotic drug treatment: A meta-analysis. Am J Psychiatry 2010;167:763–772.
5. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter
gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake
inhibitor efficacy in depressed patients. Mol Psychiatry 2007;12:247–257.